Arcxis Biotechnologies, a privately held biomedical device firm, announced today that it has completed a Series A round of financing of nearly $2,250,000. The funds, invested by Claremont Creek Ventures, will enable Arcxis to accelerate development, testing, and commercialization of their products for rapid diagnostics, pathogen handling and sample preparation.
